From: The CD44+/CD24-phenotype is enriched in basal-like breast tumors
Characteristic | All tumors (n = 240) | Negative (0%) (n = 165) | Positive (> 0%) (n = 75) | P valuea |
---|---|---|---|---|
Median age (years) | 64.1 | 64.3 | 63.5 | 1.0 |
Menopausal status | 0.098 | |||
Premenopausal | 42 (18) | 24 (15) | 18 (24) | |
Postmenopausal | 198 (83) | 141 (85) | 57 (76) | |
Tumor size | 0.58 | |||
> 20 mm | 183 (76) | 143 (75) | 40 (80) | |
≤ 20 mm | 57 (24) | 47 (25) | 10 (20) | |
Lymph node status | 0.19 | |||
Positive (n > 0) | 159 (66) | 114 (69) | 45 (60) | |
Negative (n = 0) | 81 (34) | 51 (31) | 30 (40) | |
S-phase fraction | 1.0 | |||
High (> 12%) | 37 (26) | 29 (26) | 8 (27) | |
Low (< 12%) | 106 (74) | 84 (74) | 22 (73) | |
Missing | 97 | |||
Histologic type | < 0.001 | |||
Ductal | 176 (77) | 119 (77) | 57 (78) | |
Lobular | 28 (12) | 23 (15) | 5 (7) | |
Lobular + ductal | 13 (6) | 11 (7) | 2 (3) | |
Medullary | 8 (4) | 0 (0) | 8 (11) | |
Other | 3 (1) | 2 (1) | 1 (1) | |
Missing | 12 | |||
Estrogen receptor | 0.45 | |||
Positive (> 25 fmol/mg) | 159 (68) | 112 (70) | 47 (64) | |
Negative | 74 (32) | 48 (30) | 26 (36) | |
Missing | 7 | |||
Progesterone receptor | 0.89 | |||
Positive (> 25 fmol/mg) | 114 (49) | 79 (49) | 35 (48) | |
Negative | 119 (51) | 81 (51) | 38 (52) | |
Missing | 7 | |||
HER2 | 0.002 | |||
Strong (score = 3) | 38 (16) | 34 (21) | 4 (5) | |
Weak/negative | 202 (84) | 131 (79) | 71 (95) | |
Cytokeratin 5/14b | 0.012 | |||
Strong | 28 (13) | 17 (10) | 11 (25) | |
Weak/negative | 188 (87) | 155 (90) | 33 (75) | |
Missing | 24 | |||
Epidermal growth factor receptorc | ||||
Strong | 27 (11) | 12 (7) | 15 (20) | |
Weak/negative | 210 (89) | 150 (93) | 60 (80) | |
Missing | 3 | |||
Distant metastasis | 1.0 | |||
Positive | 73 (30) | 50 (30) | 23 (31) | |
Negative | 167 (70) | 115 (70) | 52 (69) |